Xspray pharma announces positive fda meeting and plans for dasynoc nda resubmission

Stockholm--(business wire)--xspray pharma ab (publ) (nasdaq stockholm: xspray), a pharmaceutical company leveraging its proprietary hynap™ technology to develop enhanced cancer therapies, today announced significant progress following a productive meeting with the u.s. food and drug administration (fda). the company plans to resubmit its new drug application (nda) for dasynoc in q4 2024, incorporating feedback from the complete response letter (crl) issued by fda in july 2024. if the fda sets a.
CRL Ratings Summary
CRL Quant Ranking